Damage from the 2016 Kumamoto earthquake, via Wikimedia
A researcher in Japan who published at least five papers about a deadly 2016 earthquake faked some of the data, Osaka University announced late last week.
Researchers in China have retracted a 2016 paper in Oncology Letters on the anti-cancer properties of aspirin because, well, it was a disaster from top to bottom.
Get it in writing. That’s the moral in a pair of retractions in different journals after authors claimed to have received oral — but not written — ethics approval for their research.
One paper, in the International Journal of Pediatrics, a Hindawi title, came from a group in Kuwait and Greece. Titled “Prevalence and associated factors of peer victimization (bullying) among grades 7 and 8 middle school students in Kuwait, the article appeared in February 2017.
Same tea, different mug. Biomolecules, an MDPI journal, has retracted a 2018 paper by on the salubrious effects of tea because the authors had previously published the same article in a Chinese-language journal.
Publishers love their embargoes, whether they’re of papers that aren’t open access yet, or are available to the media before they’re published. Apparently, however, they also break embargoes, just like the journalists they sometimes sanction for the same sin.
Take Oxford University Press, which publishes the journal Physical Therapy for the American Physical Therapy Association (APTA). Late last month, the journal temporarily withdrew eight papers because, well, the publisher broke the journal’s embargo. Jan Reynolds, the APTA’s managing editor for the journal and director of scientific communications, explained to Retraction Watch thatContinue reading Journal temporarily withdraws eight papers after publisher mistake
Molecular Vision appears to have been flying blind when it retracted a 2013 paper by Rajendra Kadam and colleagues.
In December 2018, Kadam, a former “golden boy” in pharmaceutical research at the University of Colorado, Denver, was the subject of a finding from the U.S. Office of Research Integrity, which stated that he had fabricated his data. As part of the agreement, Kadam agreed to retract a paper in Molecular Vision. .